Bristol-Myers Squibb (BMY) Reports In-Line Q2 EPS, Updates FY EPS Guidance

Bristol-Myers Squibb (NYSE: BMY) reported Q2 EPS of $0.74, in-line with the analyst estimate of $0.74. Revenue for the quarter came in at $5.14 billion versus the consensus estimate of $5.09 billion.

GUIDANCE:

Bristol-Myers Squibb sees FY2017 EPS of $2.90-$3.00, versus the consensus of $2.95.

For earnings history and earnings-related data on Bristol-Myers Squibb (BMY) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Outlook Therapeutics (OTLK) Misses Q3 EPS by 9c
• Coherent, Inc. (COHR) Tops Q4 EPS by 12c, Offers Guidance